Board of Directors
Dr. Bernard L. Kasten, Jr.Director since 2007. Dr. Kasten is currently the Chief Executive Officer and President, the Executive Chairman and a director of the Company. Dr. Kasten has been a scientific advisor to the Company since 1999 and a member of the Company’s Advisory Committee since 2001. Dr. Kasten is a graduate of Miami University (Oxford Ohio), BA Chemistry 1967, and the Ohio State University College of Medicine MD 1971. His residency was served at the University of Miami, Florida and fellowships at the National Institutes of Health Clinical Center and National Cancer Institute, Bethesda, Maryland. Dr. Kasten is a Diplomat of the American Board of Pathology with Certification in Anatomic and Clinical Pathology with sub-specialty certification in Medical Microbiology. Dr. Kasten is an author of “Infectious Disease Handbook” 1st through 5th Editions 1994-2003 and the “Laboratory Test Handbook” 1st through 4th Editions 1984-1996 published by Lexi-Comp Inc., Hudson, Ohio. Dr. Kasten has been active with the College of American Pathologists (CAP) serving as Chairman of its Publication Committee from 1985-1993, its Management Resources Committee from 1993-1998 and its Chairman Internet Editorial Board from 1999-2003. Dr. Kasten received the College of American Pathologists Presidents Medal Awarded for Outstanding Service in 1989 and the College of American Pathologists Frank W. Hartman Award, in 1993 for Meritorious Service to the College (Founding CAP Today) the organizations highly successful monthly tabloid magazine. Dr. Kasten’s professional staff appointments have included the Cleveland Clinic, Northeastern Ohio Universities College of Medicine, the Bethesda Hospitals and Quest Diagnostics. Dr. Kasten served eight years, 1996-2004, at Quest Diagnostics Incorporated [NYSE-DGX], where he was Chief Laboratory Officer; Vice-President of Business Development for Science and Medicine and Vice-President of Medical Affairs of a Quest Diagnostics wholly-owned subsidiary, MedPlus Inc. Dr. Kasten joined SIGA Technologies, Inc. [NASDAQ-SIGA] as a Board of Directors member in May 2003, and accepted the appointment as SIGA’s Chief Executive Officer in July of 2004, serving through April 2006. Dr. Kasten has been Chairman of the Board of Directors of Cleveland Bio Labs Inc. [NASDAQ-CBLI] from 2006-2013, and currently serves as a member of the CBLI Board of Directors. He also currently serves on the Board of Directors of Enzo Biochem [NYSE-ENZ].
The GeneLink Board of Directors has concluded that Dr. Kasten is qualified and should serve, in part, because of his extensive leadership experience, both as an executive and board member, in publicly traded companies, His expertise includes medicine, laboratory operations, general medical and genetic science, intellectual property, regulatory compliance, and corporate governance. Dr. Kasten is also well qualified in view of his extensive experience in business development and strategic relationships.
Robert P. Ricciardi, Ph.D. Director since 1995. Dr. Ricciardi is currently the Chief Science Officer and a director of the Company. Dr. Ricciardi is the founder of GeneLink and is a Professor of Microbiology at the University of Pennsylvania, where he is a Department Chairman. He received his Ph.D. from the University of Illinois at Urbana. He was a Postdoctoral Fellow at Brandeis University and Harvard Medical School in the Department of Biological Chemistry where he was awarded Fellowships by the American Cancer Society, National Institutes of Health and the Charles A. King Trust. He developed one of the first genomic technologies, which was used widely to discover and map many hundreds of genes by identifying the proteins they encode. Most of Dr. Ricciardi’s research has centered on understanding basic mechanisms of cancer. He identified one of the first gene activators from a virus that can make cells cancerous by enabling them to escape the immune system. These studies in turn, disclosed a key mechanism that modulates the master regulator that governs the immune system. In addition, Dr. Ricciardi discovered a new technological platform for discovering therapeutic compounds to be used as drugs that will block viral infections. Dr. Ricciardi has served as a consultant to Children’s Hospital of Philadelphia, Smith Kline Pharmaceuticals, the NIH, and was awarded a NATO Visiting Professorship at Ferrara Medical School and has been an invitational speaker at numerous international scientific meetings and universities. He has authored over 100 publications and has been issued patents on recombinant delivery vectors for potential use as vaccines and gene therapy, therapeutic antiviral compounds, DNA collection kit, and methods for collecting DNA, assessing genes associated with oxidative stress and skin health.
The Board of Directors concluded that Dr. Ricciardi is qualified and should serve, in part, because of his extensive scientific knowledge and experience, particularly in the areas important to the Company – genetics and biochemistry. Dr. Ricciardi was also a co-founder of the Company dating back to 1994 and is the sole link to that phase of the Company’s genesis and history. As such, Dr. Ricciardi is a valuable scientific, intellectual property and regulatory resource.